A study from the Institute for Molecular Medicine Finland, FIMM, and the Helsinki University Central Hospital has created a novel individualized systems medicine strategy which enables selection of effective cancer treatments for individual patients.
Researchers found that most of the patients in the study had leukemia and benefitted from the study based on drug sensitivity. Over 200 cancer drugs were tested in the study; some approved and some on the verge of becoming approved.
"We integrate three complementary information sources, drug testing results, genomic profiling of cancer cells and clinical information. Repeated sampling of patients plays a major role in understanding and learning from each success and failure,” one of the principal investigators, Krister Wennerberg, was quoted as saying.